Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 12/20 | 0.57 |
| ▸ | PLK1 | P53350 | 1/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.50 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10112894 | 1.00 | SMYD3 (0.57) | SMYD3PLK1PRSS1PRSS2PRSS3 | |
| SCHEMBL12864600 | 0.88 | PLK1 (0.57) | PLK1TRPV1TP53 | |
| SCHEMBL21489911 | 0.86 | SMYD3 (0.71) | SMYD3PLK1PRSS1PRSS2PRSS3 | |
| SCHEMBL19701228 | 0.86 | SMYD3 (0.71) | SMYD3PLK1PRSS1PRSS2PRSS3 | |
| SCHEMBL8337991 | 0.84 | PLK1 (0.62) | SMYD3PLK1 | |
| SCHEMBL14418239 | 0.81 | PLK1 (0.50) | PLK1TRPV1TP53 | |
| SCHEMBL10112890 | 0.81 | PLK1 (0.50) | PLK1TRPV1TP53 | |
| SCHEMBL10133291 | 0.80 | PLK1 (0.49) | PLK1TRPV1TP53 | |
| SCHEMBL10113909 | 0.80 | PLK1 (0.49) | PLK1TRPV1TP53 | |
| SCHEMBL10113046 | 0.80 | PLK1 (0.49) | PLK1TRPV1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-7265130-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2007-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | SMYD3 3274/4885PLK1 4747/4885PRSS1 1128/4885 |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | SMYD3 3557/4885PLK1 4755/4885PRSS1 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.